Marinomed Biotech AG
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG00MKMQ109
MARI
Marinomed Biotech AG
GICS: -
·
Sector: -
·
Sub-Sector: -
NAME
Marinomed Biotech AG
ISIN
ATMARINOMED6
TICKER
MARI
MIC
XWBO
REUTERS
MARI.VI
BLOOMBERG
MARI AV
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Tue, 26.11.2024
Korneuburg, Austria, November 26, 2024 - Marinomed Biotech AG (the “Company”) announces the signing of an agreement for the sale of its Carragelose business to French Unither Pharmaceuticals (“Unither”), a leading contract development and manufacturing organization (CDMO) of medical devices and pharmaceutical products. The contract provides for upf...
Thu, 14.11.2024
Korneuburg, Austria, November 14, 2024 - Marinomed Biotech AG (VSE:MARI) announces that the creditors' assembly unanimously approved the restructuring plan presented at the final court hearing at the Korneuburg Regional Court on November 14, 2024. The established quota is 30%, payable in several tranches within two years. 5% is to be deposited as a...
Tue, 12.11.2024
Marinomed Biotech AG publishes clinical data for decongestant Carragelose nasal spray in peer-reviewed International Journal of General Medicine
Marinomed’s nasal spray containing Carragelose and Sorbitol significantly improves breathing due to its decongestant effect in patients suffering from allergic rhinitis
Results of the clinical study show...
Fri, 11.10.2024
Korneuburg, Austria, 11. October 2024 - Marinomed Biotech AG (the "Company") announces that, after a thorough review of existing offers, the Management Board today decided to enter contract negotiations for the sale of the Carragelose portfolio in the form of an asset deal. The Company selected the potential buyer based on a combination of favorabl...
Tue, 08.10.2024
Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal
Tacrosolv eye drops, a low-dose, aqueous Marinosolv-enabled formulation of Tacrolimus, are safe and effective in alleviating symptoms of allergic rhinoconjunctivitis
Data from ph...
Tue, 24.09.2024
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
Marinomeds new Carragelose eye drops improve dry eye-related symptoms in patients with mild to moderate dry eye syndrome by remarkable 54%
Product was well tolerated by patients and ocular surface disease index (OSDI) was significantly reduced
Eye drops hold ...
Tue, 24.09.2024
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
Marinomeds new Carragelose eye drops improve dry eye-related symptoms in patients with mild to moderate dry eye syndrome by remarkable 54%
Product was well tolerated by patients and ocular surface disease index (OSDI) was significantly reduced
Eye drops hold ...
Wed, 18.09.2024
Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by issuing 154,053 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 and...
Wed, 18.09.2024
Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by issuing 154,053 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 and...
Sun, 15.09.2024
Korneuburg, Austria, 15. September 2024 – Marinomed Biotech AG (the “Company”) announces that today the Management Board decided to set a price range of EUR 4.90 to a maximum of EUR 5.20 per new share for a potential capital increase of up to 154,053 new shares to be issued under the Authorized Capital 2024 and subject to the direct exclusion of th...
Information on product placements
